{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:21:46Z","timestamp":1784697706942,"version":"3.55.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>We investigated toxicity and patient-reported outcomes in patients with localized prostate cancer treated with moderately hypofractionated radiotherapy, focusing on clinically meaningful deterioration assessed using the minimum clinically important difference (MCID) at 24\u00a0months. Between January 2019 and December 2021, 58 patients were prospectively enrolled at a single institution and received volumetric-modulated arc therapy and image-guided radiotherapy, delivering 60\u00a0Gy in 20 fractions. The median follow-up period was 48\u00a0months. Toxicities were evaluated using the Common Terminology Criteria for Adverse Events version 5.0. Health-related quality of life (HR-QOL) was assessed at baseline and at 3, 6, 12, 24 and 36\u00a0months using the Short Form-8 Health Survey (SF-8) and the Expanded Prostate Cancer Index Composite (EPIC). Grade 2 acute gastrointestinal (GI) and genitourinary (GU) toxicities occurred in 0% and 5.2% of patients, respectively. Late Grade 2 GI and GU toxicities occurred in 1.7% and 6.9% of patients, respectively. No Grade\u2009\u2265\u00a03 toxicities were reported. At 24\u00a0months, a\u2009\u2265\u20092\u2009\u00d7\u2009MCID decline in SF-8 physical and mental component scores was observed in 12.2% (95% confidence interval [CI]: 3.2\u201321.2%) and 14.3% (95% CI: 4.5\u201324.1%), respectively. In the EPIC domains, \u2265 2\u2009\u00d7\u2009MCID declines occurred in 23.8% (95% CI: 10.9\u201336.7%) for bowel and 8.5% (95% CI: 0.5\u201316.5%) for urinary summary scores. A 60\u00a0Gy regimen delivered in 20 fractions is feasible and well tolerated, with low toxicity and stable HR-QOL, although these preliminary findings are based on a limited observation period and sample size. Longer follow-up and larger studies are warranted.<\/jats:p>","DOI":"10.1093\/jrr\/rraf059","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T11:52:55Z","timestamp":1755777175000},"page":"673-681","source":"Crossref","is-referenced-by-count":2,"title":["Toxicity and patient-reported outcomes after moderately hypofractionated radiotherapy (60\u00a0Gy in 20 fractions) for prostate cancer: prospective observational study"],"prefix":"10.1093","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4840-8481","authenticated-orcid":false,"given":"Koyo","family":"Kikuchi","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Iwate Medical University School of Medicine , 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Segawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iwate Medical University School of Medicine , 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Ieko","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iwate Medical University School of Medicine , 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirobumi","family":"Oikawa","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iwate Medical University School of Medicine , 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6605-1837","authenticated-orcid":false,"given":"Ryuji","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Radiology, Morioka Red Cross Hospital , 6-1-1 Sanbonyanagi, Morioka, Iwate 020-8560 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Ariga","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Iwate Medical University School of Medicine , 2-1-1 Idaidori, Yahaba-cho, Shiwa-gun, Iwate 028-3695 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"2025112604221270100_ref1","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2018","author":"National Comprehensive Cancer Network","year":"2018"},{"key":"2025112604221270100_ref2","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"2025112604221270100_ref3","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","article-title":"Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline","volume":"8","author":"Morgan","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"2025112604221270100_ref4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025112604221270100_ref5","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","article-title":"Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer","volume":"35","author":"Catton","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025112604221270100_ref6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(25)00034-8","article-title":"Hypofractionated radiotherapy for prostate cancer (HYDRA): an individual patient data meta-analysis of randomised trials in the MARCAP consortium","volume":"26","author":"Kishan","year":"2025","journal-title":"Lancet Oncol"},{"key":"2025112604221270100_ref7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10147-024-02517-z","article-title":"A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer","volume":"29","author":"Nakamura","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"2025112604221270100_ref8","volume-title":"Manual of the SF-8","author":"Fukuhara","year":"2004"},{"key":"2025112604221270100_ref9","doi-asserted-by":"publisher","first-page":"657","DOI":"10.5980\/jpnjurol1989.96.657","article-title":"The Japanese translation and cultural adaptation of expanded prostate cancer index composite (EPIC)","volume":"96","author":"Takegami","year":"2005","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"2025112604221270100_ref10","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.prro.2013.01.003","article-title":"Reduced acute toxicity associated with the use of volumetric modulated arc therapy for the treatment of adenocarcinoma of the prostate","volume":"3","author":"Hall","year":"2013","journal-title":"Pract Radiat Oncol"},{"key":"2025112604221270100_ref11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.prro.2014.03.003","article-title":"A dosimetric comparison of volumetric modulated arc therapy with step-and-shoot intensity modulated radiation therapy for prostate cancer","volume":"5","author":"Mellon","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"2025112604221270100_ref12","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.ijrobp.2016.12.024","article-title":"Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial","volume":"97","author":"Hamstra","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025112604221270100_ref13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.brachy.2019.06.006","article-title":"Patient-reported health-related quality of life up to three years after the treatment with permanent brachytherapy: outcome of the large-scale, prospective longitudinal study in Japanese-prostate cancer outcome study by permanent I-125 seed implantation (J-POPS)","volume":"18","author":"Koga","year":"2019","journal-title":"Brachytherapy"},{"key":"2025112604221270100_ref14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/RRU.S168651","article-title":"Quality of life worsened the most severely in patients immediately after intensity-modulated radiotherapy for prostate cancer","volume":"10","author":"Nakai","year":"2018","journal-title":"Res Rep Urol"},{"key":"2025112604221270100_ref15","doi-asserted-by":"crossref","first-page":"1250e1261","DOI":"10.1056\/NEJMoa074311","article-title":"Quality of life and satisfaction with outcome among prostate-cancer survivors","volume":"358","author":"Sanda","year":"2008","journal-title":"N Engl J Med"},{"key":"2025112604221270100_ref16","doi-asserted-by":"crossref","first-page":"4687e4696","DOI":"10.1200\/JCO.2009.25.3245","article-title":"Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment","volume":"28","author":"Pardo","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025112604221270100_ref17","doi-asserted-by":"publisher","first-page":"4286","DOI":"10.1002\/cncr.29672","article-title":"Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners","volume":"121","author":"Donovan","year":"2015","journal-title":"Cancer"},{"key":"2025112604221270100_ref18","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1111\/jsm.12645","article-title":"Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy","volume":"11","author":"Benedict","year":"2014","journal-title":"J Sex Med"}],"container-title":["Journal of Radiation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/66\/6\/673\/64377164\/rraf059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jrr\/article-pdf\/66\/6\/673\/64377164\/rraf059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T09:22:25Z","timestamp":1764148945000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jrr\/article\/66\/6\/673\/8263183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,24]]},"published-print":{"date-parts":[[2025,11,25]]}},"URL":"https:\/\/doi.org\/10.1093\/jrr\/rraf059","relation":{},"ISSN":["0449-3060","1349-9157"],"issn-type":[{"value":"0449-3060","type":"print"},{"value":"1349-9157","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,24]]}}}